Several clinical trials (8–13) and a meta-analysis (7) have reported that combining SGLT2 inhibitors with insulin as a treatment regimen for T2D would impede this weight gain and would result in a significant decrease in body weight (Table 1). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.